Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Cogent’s first clinical readout in systemic mastocytosis drives stock bump

Ex-Array team believes in-licensed therapy can be best-in-class in hematological disorder

By Paul Bonanos, Associate Editor
June 10, 2022 5:40 PM UTC
Updated on Jun 10, 2022 at 8:53 PM UTC

Led by a team that includes former Array executives, Cogent believes new clinical data support its conviction that its selective c-KIT inhibitor can be a best-in-class therapy for systemic mastocytosis.

Data presented Friday from the Phase II APEX study showed that bezuclastinib (CGT9486) led to biomarker effects in all evaluable patients with advanced systemic mastocytosis. The news drove shares of Cogent Biosciences Inc. (NASDAQ:COGT) up $2.91 (59%) to $7.87, lifting its market cap above $360 million...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cogent Biosciences Inc.